SCHEMBL4170159

SCHEMBL4170159

Cc1cc(Nc2cnc(-c3ccc4scnc4c3)c(N)n2)n[nH]1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ DYRK2 Q92630 9/20 0.39
▸ KDR P35968 5/20 0.38
▸ AURKA O14965 3/20 0.38
▸ AURKB Q96GD4 3/20 0.38
▸ FLT4 P35916 2/20 0.38
▸ ITK Q08881 1/20 0.38
▸ RIPK2 O43353 3/20 0.37
▸ LCK P06239 3/20 0.37
▸ TGFBR1 P36897 3/20 0.37
▸ RIPK1 Q13546 1/20 0.36
▸ RIPK3 Q9Y572 1/20 0.36
▸ JAK2 O60674 1/20 0.35
▸ JAK3 P52333 1/20 0.35
▸ PIM1 P11309 1/20 0.35
▸ PIM2 Q9P1W9 1/20 0.35
▸ EGFR P00533 1/20 0.35
▸ INSR P06213 1/20 0.35
▸ IGF1R P08069 1/20 0.35
▸ SRC P12931 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4169624 0.81 ITK (0.43) KDRAURKAAURKBFLT4ITK
SCHEMBL4168909 0.79 IKBKB (0.46) AURKAAURKBITKJAK2JAK3
SCHEMBL4179012 0.79 MEN1 (0.46) AURKAITKJAK2JAK3SRC
SCHEMBL4303875 0.79 JAK2 (0.49) AURKAAURKBITKJAK2JAK3
SCHEMBL4162013 0.79 ITK (0.39) ITKRIPK2JAK2JAK3
SCHEMBL4169281 0.78 MEN1 (0.43) KDRAURKAAURKBFLT4ITK
SCHEMBL4179956 0.78 JAK2 (0.43) AURKAAURKBITKJAK2JAK3
SCHEMBL4167808 0.78 ITK (0.40) AURKAAURKBITKJAK2JAK3
SCHEMBL4167995 0.78 TGFBR1 (0.43) KDRAURKBFLT4ITKTGFBR1
SCHEMBL4300039 0.77 RET (0.46) AURKAAURKBITKEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2009-10-29 — — US claimed
WO-2009089042-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2009-07-16 — — WO claimed
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2009-10-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH MAP3K1, MAP3K15, MAP3K5 DYRK2 1220/4885KDR 1009/4885AURKA 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback